Functional interaction between nucleus tractus solitarius NK1 and 5-HT3 receptors in the inhibition of baroreflex in rats.
OBJECTIVE
Previous data showed that in the nucleus tractus solitarius (NTS), 5-HT(3) receptors are critically involved in the inhibition of cardiac baroreceptor reflex response occurring during the defense reaction. Since stimulation of NTS NK(1) receptors has been found to inhibit the baroreflex bradycardia, we examined in this study whether this reflex response is inhibited during the defense reaction via an interaction between NK(1) and 5-HT(3) receptors.


METHODS
For this purpose, we analyzed in urethane-anaesthetized rats the effects of intra-NTS GR205171, a selective NK(1) receptor antagonist, on the baroreflex bradycardia inhibition observed either during the defense reaction triggered by electrical stimulation of the dorsal periaqueductal grey matter (dPAG) or after NTS 5-HT(3) receptor activation.


RESULTS
Intra-NTS GR205171, reversed, in dose-dependent manner, the inhibitory effect of dPAG stimulation on baroreflex bradycardia. This reversion was of 49% when both sinus carotid and aortic baroreceptors were stimulated by phenylephrine, and of 84% when aortic depressor nerve was stimulated. Similarly, intra-NTS GR205171 reversed partially or almost totally the inhibitory effect of local microinjections of phenylbiguanide, a 5-HT(3) receptor agonist, on baroreflex bradycardia induced either by phenylephrine administration or aortic nerve stimulation, respectively.


CONCLUSIONS
These results strongly suggest that NK(1) receptors contribute downstream to the 5-HT(3) receptor-mediated inhibition of the aortic but not carotid cardiac baroreflex response occurring during the defense reaction, therefore implying that baroreceptor afferent inputs may be differentially modulated depending on their origin. This differentiation may be useful for a better understanding of baroreflex dysfunction in disease-induced conditions.
Comet
M-A
MA
Inserm U.288, Faculté de Médecine Pitié-Salpêtrière, 91 Boulevard de l'Hôpital, 75634 Paris Cedex 13, France.
Laguzzi
R
R
Hamon
M
M
Sévoz-Couche
C
C
D000818:Animals; D001011:Aorta / Q000294:innervation; D017704:Baroreflex / Q000187:drug effects / Q000502:physiology*; D001919:Bradycardia / Q000139:chemically induced / Q000503:physiopathology; D004558:Electric Stimulation; D004924:Escape Reaction / Q000187:drug effects / Q000502:physiology; D017829:Granisetron / Q000494:pharmacology; D008297:Male; D008845:Microinjections; D064729:Neurokinin-1 Receptor Antagonists; D010880:Piperidines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D018040:Receptors, Neurokinin-1 / Q000378:metabolism / Q000502:physiology*; D044406:Receptors, Serotonin, 5-HT3 / Q000378:metabolism / Q000502:physiology*; D058831:Serotonin 5-HT3 Receptor Antagonists; D017552:Solitary Nucleus / Q000378:metabolism* / Q000502:physiology; D013373:Substance P / Q000494:pharmacology; D013777:Tetrazoles / Q000494:pharmacology
D017829:Granisetron; D064729:Neurokinin-1 Receptor Antagonists; D010880:Piperidines; D018040:Receptors, Neurokinin-1; D044406:Receptors, Serotonin, 5-HT3; D058831:Serotonin 5-HT3 Receptor Antagonists; D013373:Substance P; D013777:Tetrazoles; C103207:vofopitant